Latest & greatest articles for finasteride

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on finasteride or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on finasteride and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for finasteride

1. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. (PubMed)

Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Finasteride at 1 mg/day and 5% topical minoxidil are effective in male androgenetic alopecia (MAGA). However, studies describing their effects in Chinese individuals are scarce. 450 Chinese MAGA patients were randomly assigned to receive finasteride (n = 160), minoxidil (n = 130) and combined medication (n = 160) for 12 months. The patients (...) returned to the clinic every 3 months for efficacy evaluation. And efficacy was evaluated in 428 men at treatment end, including 154, 122, and 152 in the finasteride, 5% minoxidil, and combination groups, respectively. All groups showed similar baseline characteristics, including age at enrollment, and duration and severity of alopecia (p > 0.05). At 12 months, 80.5, 59, and 94.1% men treated with finasteride, 5% minoxidil and the combination therapy showed improvement, respectively. Adverse reactions

2015 Dermatologic therapy

2. Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia

Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia TITLE: Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia: Comparative Clinical Effectiveness and Safety DATE: 07 March 2014 RESEARCH QUESTIONS 1. What is the comparative clinical effectiveness and safety of dutasteride and finasteride for men with benign prostatic hyperplasia? 2. What is the clinical effectiveness and safety of dutasteride versus placebo for men with benign prostatic hyperplasia? 3. What (...) is the clinical effectiveness and safety of finasteride versus placebo for men with benign prostatic hyperplasia? KEY MESSAGE Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo for the treatment of benign prostatic hyperplasia. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. (PubMed)

Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL. Use of a topical formulation has been proposed to minimize unwanted effects.Our objective was to compare the efficacy and safety of topical 0.25 (...) % finasteride combined with 3% minoxidil solution and 3% minoxidil solution as monotherapy in the treatment of FPHL.This was a prospective, randomized, double-blind study in 30 postmenopausal women with FPHL. Each participant was randomized to receive either topical 0.25% finasteride combined with topical 3% minoxidil or topical 3% minoxidil solution as monotherapy for 24 weeks. To determine efficacy, the hair density and diameter was measured and global photographic assessment was conducted at baseline

2018 American journal of clinical dermatology

4. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. (PubMed)

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment.We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha (...) reductase inhibitor) and placebo in men with androgenetic alopecia.Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes.In total, 917 men were randomized. Hair count

2014 Journal of the American Academy of Dermatology

5. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety

Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo

2014 Health Technology Assessment (HTA) Database.

6. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. (PubMed)

A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. The synergism of combined use between oral finasteride and topical minoxidil has been established in treating androgenetic alopecia among men. However, the concern regarding adverse effects of finasteride use has been rising.To compare the efficacy and safety of topical solution (...) of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in men with androgenetic alopecia.Forty men aged 18-60 years with androgenetic alopecia were randomized to 24 weeks of treatment with a finasteride/minoxidil or minoxidil solution twice daily. Primary efficacy endpoint was the change from baseline in hair density and hair diameter at week 24. Secondary endpoints included global photographic assessment by treatment-blinded investigators and subjects. Changes in plasma

2018 Journal of the European Academy of Dermatology and Venereology

7. "Post-finasteride syndrome": what to tell our female patients? (PubMed)

"Post-finasteride syndrome": what to tell our female patients? 29624646 2018 09 17 1365-2133 179 3 2018 Sep The British journal of dermatology Br. J. Dermatol. 'Post-finasteride syndrome': what to tell our female patients? 785-786 10.1111/bjd.16658 Mervis J S JS http://orcid.org/0000-0002-4395-8871 Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, U.S.A. Borda L J LJ Department of Dermatology & Cutaneous Surgery, University of Miami

2018 British Journal of Dermatology

8. 3-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. (PubMed)

3-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. We evaluated the long-term outcomes of treatment of lower urinary tract symptoms due to benign prostatic hyperplasia to compare a 1-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the MTOPS (Medical Therapy (...) of Prostatic Symptoms) study.Results in the treatment arm of a randomized, controlled trial of thermal therapy using the Rezūm® System were compared to MTOPS subjects treated with doxazosin and/or finasteride. Evaluations were restricted to medical therapy subjects, representing 1,140 of the original 3,047 (37.4%), with a prostate volume of 30 to 80 cc and an International Prostate Symptom Score of 13 or greater to include men who met key criteria of the Rezūm and MTOPS trials. Outcomes were compared

2018 Journal of Urology

9. Finasteride: rare reports of depression and suicidal thoughts

Finasteride: rare reports of depression and suicidal thoughts Finasteride: rare reports of depression and suicidal thoughts - GOV.UK GOV.UK uses cookies to make the site simpler. Search Finasteride: rare reports of depression and suicidal thoughts We have received reports of depression and, in rare cases, suicidal thoughts in men taking finasteride 1 mg (Propecia) for male pattern hair loss. Be aware that depression is also associated with finasteride 5 mg (Proscar). Published 24 May 2017 From (...) : Therapeutic area: , , Contents Advice for healthcare professionals: since finasteride has been marketed there have been a number of spontaneous adverse drug reaction reports suggesting a possible link to depression, and in rare cases, suicidal thoughts advise patients to stop finasteride 1 mg (Propecia) immediately if they develop depression and inform a healthcare professional be aware that the product information for finasteride 5 mg (Proscar) already lists depression as a possible adverse reaction

2017 MHRA Drug Safety Update

10. Assessing finasteride-associated sexual dysfunction using the FAERS database. (PubMed)

Assessing finasteride-associated sexual dysfunction using the FAERS database. Postmarketing reports suggest that finasteride causes sexual dysfunction despite a low incidence reported in clinical trials. Therefore, the extent of risk remains unknown.To determine whether the risk of sexual dysfunction is higher among individuals treated with finasteride compared to a baseline risk for all other drugs using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.A (...) case by non-case disproportionality approach was used whereby a reporting odds ratio (ROR) with 95% confidence interval (CI) was calculated. The National Ambulatory Medical Care Survey (NAMCS) was used to confirm results.A significant disproportionality in reporting of sexual dysfunction with the use of finasteride was observed whether finasteride was indicated for hair loss (ROR = 138.17, 95% CI: 133.13, 143.4), prostatic hyperplasia (ROR = 93.88, 95% CI: 84.62, 104.16) or any indication (ROR

2017 Journal of the European Academy of Dermatology and Venereology

11. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. (PubMed)

Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Treatment of male androgenetic alopecia with 5α-reductase inhibitors is efficacious. However, the risk of adverse sexual effects remains controversial. This systematic review and meta-analysis investigated the risk of adverse sexual effects due to treatment of androgenetic alopecia in male patients with finasteride, 1 mg/day, or dutasteride, 0.5 mg/day (...) . Fifteen randomized double-blinded placebo-controlled trials (4,495 subjects) were meta-analysed. Use of 5α-reductase inhibitors carried a 1.57-fold risk of sexual dysfunction (95% confidence interval (95% CI) 1.19-2.08). The relative risk was 1.66 (95% CI 1.20-2.30) for finasteride and 1.37 (95% CI 0.81-2.32) for dutasteride. Both drugs were associated with an increased risk, although the increase was not statistically significant for dutasteride. As studies into dutasteride were limited, further

Full Text available with Trip Pro

2018 Acta Dermato-Venereologica

12. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. (PubMed)

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. Finasteride has been found to reduce the risk of low-grade prostate cancer but to have no impact on overall survival. The long-term adverse and beneficial consequences of finasteride have not been examined.We used a linkage between data from the Prostate Cancer Prevention Trial (PCPT) and Medicare claims. Patients were examined by randomized study arm (finasteride vs placebo for 7 years) for long-term (...) between finasteride and placebo participants with respect to important baseline factors or amount of Medicare follow-up assessment time. Finasteride patients had a 10% higher risk of new claims for depression (hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.01 to 1.19, P = .04) and a 6% lower risk of procedures for BPH-related events (primarily lower urinary tract symptoms; HR = 0.94, 95% CI = 0.89 to 1.00, P = .03). No other differences were found in rates of long-term consequences

Full Text available with Trip Pro

2016 Journal of the National Cancer Institute

13. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. (PubMed)

Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Finasteride and dutasteride are inhibitors of the enzyme 5-alpha-reductase which inhibits the conversion of testosterone to dihydrotestosterone. Dutasteride inhibits both type I and type II 5-alpha-reductase while finasteride inhibits only the type II enzyme. As both isoenzymes are present in hair follicles (...) , it is likely that dutasteride is more effective than finasteride.To compare the efficacy, safety and tolerability of dutasteride and finasteride in men with androgenetic alopecia.Men with androgenetic alopecia between 18 and 40 years of age were randomized to receive 0.5 mg dutasteride or 1 mg finasteride daily for 24 weeks. The primary efficacy variables were hair counts (thick and thin) in the target area from modified phototrichograms and global photography evaluation by blinded and non-blinded

Full Text available with Trip Pro

2016 Indian journal of dermatology, venereology and leprology

14. Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01534351 Recruitment Status : Terminated (Business Reasons) First Posted

2012 Clinical Trials

15. Finasteride: potential risk of male breast cancer

Finasteride: potential risk of male breast cancer Finasteride: potential risk of male breast cancer - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Finasteride: potential risk of male breast cancer Patients should be advised to promptly report to their doctor any changes in their breast tissue such as lumps, pain, or nipple discharge. Published 11 December 2014 From: Therapeutic area: , Article date: December 2009 Finasteride is an inhibitor of type II 5α-reductase, an enzyme (...) that metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT), resulting in a reduction in DHT concentrations in serum and target tissues. 5 mg finasteride (Proscar) is used for the treatment and control of benign prostatic hyperplasia because enlargement of the prostate gland is dependent on conversion of testosterone to DHT. Finasteride can also reduce scalp and serum DHT concentrations, and the 1 mg dose (Propecia) is indicated for the treatment of men with androgenetic alopecia

2010 MHRA Drug Safety Update

16. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. (PubMed)

Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. Topical minoxidil and oral finasteride have been used to treat men with androgenetic alopecia (AGA). There are concerns about side effects of oral finasteride especially erectile dysfunction.To compare the efficacy and safety of the 24 weeks application of 3% minoxidil lotion (MNX) versus combined 3% minoxidil and 0.1% finasteride lotion

2012 Journal of the Medical Association of Thailand = Chotmaihet thangphaet

17. Finasteride: clinical and economic impacts

Finasteride: clinical and economic impacts Finasteride: clinical and economic impacts Finasteride: clinical and economic impacts Otten N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A new medical treatment for benign (...) prostatic hypertrophy (BPH), finasteride, was compared with the two most common treatment options that is transurethral resection of the prostate (TURP) and watchful waiting, for patients with varying degrees of symptom severity. Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Males receiving either finasteride, TURP or watchful waiting for the treatment of BPH. Patients had either mild, moderate or severe

1996 NHS Economic Evaluation Database.

18. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer

Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer Reed SD, Scales CD, Stewart SB, Sun J, Moul JW, Schulman KA, Xu J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of chemoprevention of prostate cancer using finasteride, compared with no chemoprevention, considering risk groups. At a threshold of 100,000 US dollars per quality-adjusted life

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

19. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. (PubMed)

Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. We examined the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 (Medical Outcomes Study Short-Form 36) and 2 disease specific instruments (BII, benign prostatic hyperplasia Impact Index and I-PSS-QoL, International Prostate Symptom Score-QoL) during 4 years.The MTOPS (...) scores when drug groups were compared with the placebo group.The quality of life of men treated with doxazosin, finasteride, and the drugs combined generally improved when assessed with the BII and the I-PSS-QoL compared with those treated with placebo. Quality of life did not show improvement when measured by the MOS-SF-36.Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

2013 Journal of Urology

20. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. (PubMed)

Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Androgenic treatment of female-to-male transgender patients may result in androgenetic alopecia (AGA). Use of 5-alpha-reductase inhibitors are useful as oral treatment of AA in men. There are no previous studies of the use of finasteride in transgender men as treatment of AGA.To evaluate the effectiveness and safety of an oral 5α-reductase inhibitor (finasteride) for AA developed (...) history of AGA. All the patients improved one grade on the Norwood-Hamilton scale after a mean of 5.5 months (range 4-6 months) since the start of finasteride treatment. Two patients stopped treatment for economic reasons and one stopped due to dyspepsia. No sexual or other adverse effects were observed. Patients were given periodic physical and analytical examinations by endocrinologists without any significant finding. Mean follow-up of patients was 16.2 months.AA in transgender men has a delayed

2017 Clinical & Experimental Dermatology